Newsroom
-
January 3 , 2019
2019 M&A starts with a bang as BMS and Celgene agree $74bn merger
- The pairing will create a company with annual sales north of $34 billion, behind Pfizer, Novartis and Roche in terms of 2017 prescription drug sales and ahead of Merck & Co and Johnson & Johnson. There’s also plenty of scope for cost-cutting – the two companies think they can find $2.5 billion in “synergies” by 2022.
Read more -
October 1 , 2018
Three Emerging Positive Trends to Watch in China Opening Up Huge Long-term Market Opportunity
- Three positive developments in China have evolved recently that could benefit the development, regulatory, reimbursement and - perhaps just as importantly-investment framework for biopharma. While still early, the Chinese govt is shifting from a network mostly "closed" to US Biopharma towards a more "open" and pro-innovation stance for medicine that could th
Read more